Qyuns Therapeutics Co., Ltd. Class H · HKEX:2509
Qyuns Therapeutics Co., Ltd. Class H — FY2024 Earnings Presentation
34 slides from Qyuns Therapeutics Co., Ltd. Class H's earnings presentation, Mar 31, 2025
Slide 1: 2024 Annual Results
2024 ANNUAL RESULTS 31 March 2025
Slide 2: Disclaimer
Disclaimer NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION OR DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAWS By attending this presentation or by reading this document, you (1) agree to be bound by the
Slide 3: Our Mission and Vision
Our Mission TO PURSUE SCIENTIFIC INNOVATION AND DELIVER AFFORDABLE AND QUALITY THERAPEUTICS Our Vision TO ADDRESS UNMET MEDICAL NEEDS AND BUILD LEADERSHIP IN AUTOIMMUNE AND ALLERGIC DISEASE AREAS 2
Slide 4: Qyuns at a Glance
Qyuns at a Glance A clinical-stage biotech company exclusively focused on biologic therapies for autoimmune and allergic diseases Exclusive Focus Full Coverage Huge Market Comprehensive Pipeline Focus on autoimmune and allergic Cover four major disease areas in Global market size of US$187.5 1 produ
Slide 5: Exclusive focus on autoimmune and allergic disease therapies
Exclusive focus on autoimmune and allergic disease therapies, covering four major disease areas and key therapeutic pathways Therapeutic Skin pipelines prioritized to build leading position in industry IL-12/IL-23p40 Psoriasis Ankylosing Spondylitis IL-23p19 Psoriasis IL-17A Lupus Nephritis Atopic D
Slide 6: Seasoned Management Team with Extensive Industry Experience
Seasoned Management Team with Extensive Industry Experience and Successful Entrepreneurial Track Records Jianwei Li, Ph.D. Jiwan Qiu Deputy General Manager Executive Director, Chairman, General Manager Min Fang 30 years of extensive R&D experience in biotechnology industry Deputy General Manager wit
Slide 7: 2024 of Qyuns: Solid Growth & Strong Delivery
2024 of Qyuns: Solid Growth & Strong Delivery Pipeline Advancement • Key clinical trials on schedule • Differentiation & Innovation • Improve efficiency and focus on core pipeline Strategic Cooperation • R&D-Production-Commercialization Integrated Strategic Alliance • Cash inflow from cooperation pa
Slide 8: Overview
01 Innovative R&D Strength: Strong Delivery on Core Pipeline 02 Strategic Partnership Capability: Future Commercialization Guarantee Self-Sustaining Operations: Overview 03 Stronger Financial Performance Insurance 04 Financial Results 05 Future Outlook 7
Slide 9: Innovative R&D Strength: Strong Delivery on Core Pipeline
Innovative R&D Strength: 01 Strong Delivery on Core Pipeline 8
Slide 10: 2024: Year of Dual Debut - Product Launch & IPO
2024: Year of Dual Debut - Product Launch & IPO Company Listed on HKEX • On 20 March 2024, Qyuns successfully completed its IPO and was officially listed on the Hong Kong Stock Exchange (HKEX) • First 18A Biotech IPO of the Year of the Dragon Product Launch • 29 October 2024，SAILEXIN - China’s FIRST
Slide 11: Comprehensive and Synergized Pipeline
Comprehensive and Synergized Pipeline Phase I BLA Commercialization Drug Target Indication Preclinical IND Approval Phase II Phase III Recent Progress la lb Approval Rights Ph III primary endpoint AS data read-out in Feb 2025 QX002N IL-17A Timing of Phase I to be LN determined Moderate-to- Phase lll
Slide 12: Product Matrix by Therapeutic Areas
Product Matrix by Therapeutic Areas The position of our pipeline assets in context Skin Rheumatic Respiratory Digestive Ps AD PN CSU Pruritus AS SLE LN CRSwNP Asthma COPD CD UC QX002N IL-17A QX005N IL-4Rα QX001S IL-12/IL-23p40 QX004N IL-23p19 QX006N IFNAR1 QX008N TSLP QX007N IL-33 QX013N c-kit QX010
Slide 13: QX001S – First Ustekinumab Biosimilar Approved in China
QX001S – First Ustekinumab Biosimilar Approved in China & Expected Blockbuster Market Opportunities and Competition Competitive Advantages Market Opportunities Ustekinumab Global Sales The first marketed Ustekinumab Biosimilar in China (SAILEXIN) The Ps patient population in China is ✓ Commercializa
Slide 14: QX005N – One of the Two IL-4Rα mAbs with BTD in China
QX005N – One of the Two IL-4Rα mAbs with BTD in China QX005N Strategic Cooperation • IL-4Rα controls the signaling of both IL-4 and IL-13, which is critical in the initiation of type 2 inflammation • QX005N is designed to inhibit IL-4Rα, a well-validated, ⚫ In July 2024, the exclusive joint developm
Slide 15: QX005N – 1st Biologic Drug Candidate for PN
QX005N – 1st Biologic Drug Candidate for PN Developed by Chinese Domestic Company Market Opportunities and Competition Unmet Medical Needs • Development of the PN drug market in China is still at an Limitation of Prevalence of PN in China, 2017-2030E current early stage Thousand treatment • Current
Slide 16: QX005N – Treatment for Moderate-to-Severe AD
QX005N – Treatment for Moderate-to-Severe AD Market Opportunities and Competition Clinical Development Market Opportunities IL-4Rα mAb Sales Soaring in China AD patients in China reached 70.3 million in Phase III > FPI in May 2024 2022 and is anticipated to reach 78.5 million CAGR=325.0% 248.1 in 20
Slide 17: QX002N – IL-17A mAb for AS
QX002N – IL-17A mAb for AS Market Opportunities and Competition Competitive Advantages Market Opportunities IL-17A vs. TNF The AS patient population in China reached 3.9 million in 2022, mainly younger ✓ Guided as 2L standalone treatment for AS, IL-17A inhibitors have shown adults clear clinical ben
Slide 18: QX004N – IL-23p19 mAb for Psoriasis and Crohn's Disease
QX004N – IL-23p19 mAb for Psoriasis and Crohn’s Disease IL-23p19 is currently a better target for psoriasis. Same target competitor The treatment effect of psoriasis will be further improved, The global sales of Skyrizi®, the same target competitor, were $1.59 and it is conducive to long-term manage
Slide 19: QX008N – TSLP mAb for Respiratory Diseases
QX008N – TSLP mAb for Respiratory Diseases Same target competitor •TSLP is a cytokine expressed by the airway epithelium and sits The global sales of Tezspire®, a competitor with the same target, were $174 at the top of multiple inflammatory cascades million in 2022 and $653 million in 2023, with an
Slide 20: QX013N – First Biologic Drug Candidate Targeting c-kit in China
QX013N – First Biologic Drug Candidate Targeting c-kit in China QX013N is a humanized IgG1 monoclonal antibody independently developed by Qyuns and is the first biologic drug candidate targeting c-kit in China. We completed FPI in June 2024 for the indication of chronic spontaneous urticaria (CSU).
Slide 21: Strategic Partnership Capability: Future Commercialization Guarantee
Strategic Partnership Capability: 02 Future Commercialization Guarantee 20
Slide 22: R&D-Production-Commercialization Integrated Strategic Alliance
R&D-Production-Commercialization Integrated Strategic Alliance Early Research Pre-clinical Study Clinical Development Production Commercialization Innovative structural platform for rabbit 9 self-developed Process development & mAbs & BsAbs development product pipelines pilot platform Integrated ant
Slide 23: Strategic Collaborations – Further Strengthening Commercialization Certainty
Strategic Collaborations – Further Strengthening Commercialization Certainty QX008N 24 Jan 2024 We entered into a technology transfer agreement with Joincare to grant Joincare an exclusive license to develop, manufacture and commercialize QX008N in China, Hong Kong and Macau. QX004N 24 Apr 2024 We e
Slide 24: Self-Sustaining Operations: Stronger Financial Performance Insurance
Self-Sustaining Operations: 03 Stronger Financial Performance Insurance 23
Slide 25: Cellularforce: Commercial Production Capacity Supporting CDMO Business
Cellularforce: Commercial Production Capacity Supporting CDMO Business Transformation cGMP-standard manufacturing facility with excelled CMC capability One of only a few Chinese biotech companies that are focused on and quality management will secure high quality, cost controllable autoimmune and al
Slide 26: Strong Operational Cash-generating Capability Delivering Sustained Capital Reserves
Strong Operational Cash-generating Capability Delivering Sustained Capital Reserves Income from BD Income from CDMO RMB 130M + RMB 23M + 25
Slide 27: Financial Results
0) =. © Financial Results
Slide 28: 1st Time Revenue Realization Further Strengthens Capital Reserve
1st Time Revenue Realization Further Strengthens Capital Reserve Mil RMB 180 158.79 160 In 2024, the total revenue of Qyuns was RMB 158.79M, further enhancing the company’s capital reserve. 140 120 The revenue in 2024 mainly came from licensing-out 100 deals, income from provision of research and 80
Slide 29: Effective Expense Management Improves Operational Efficiency
Effective Expense Management Improves Operational Efficiency Mil RMB R&D Expenses of 2023 – 2024 Mil RMB Administrative Expenses of 2023 – 2024 380 180 364.4 164.6 360 160 340 334.28 140 115.93 320 120 300 100 280 80 260 60 240 40 220 20 200 0 2023.12.31 2024.12.31 2023.12.31 2024.12.31 In 2024, Qyu
Slide 30: 47.63% Increase in Cash Reserves Reflects Excellent Financial Management
47.63% Increase in Cash Reserves Reflects Excellent Financial Management Cash and cash equivalents and financial assets As of December 31, 2024, cash and cash equivalents and financial assets at fair value recorded in profit or loss at fair value through profit or loss was RMB 556.13M, representing
Slide 31: Revenue from BD Led to Improvement of 38.1% in Operating Cashflow
Revenue from BD Led to Improvement of 38.1% in Operating Cashflow Mil RMB Net cash outflow from operating activities 350 In 2024, the net cash outflow from operating activities of Qyuns 300.68 300 was RMB 186.09M, which represents a significant decrease of 38.1% compared to RMB 300.68M last year. 25
Slide 32: Future Outlook
0) =" © Future Outlook
Slide 33: Future Outlook
Future Outlook Secure the fundamentals to ensure the clinical progress and 1 regulatory submission of existing products on schedule Establish diversified commercialization partnerships to expand 2 innovative drug markets domestically and globally Focus on autoimmune diseases and deliver differentiat
Slide 34: IR@qyuns.net
IR@qyuns.net 33